ANAVEX LIFE SCIENCES CORP. — Investor Relations & Filings
Filings indexed
577
across all filing types
Latest filing
2025-08-22
Director's Dealing
Country
US
United States of America
Listing
US
AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for central nervous system (CNS) disorders. The company develops targeted drug candidates for neurodegenerative and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. Anavex's approach is centered on precision medicine, utilizing small molecule drugs designed to restore cellular homeostasis. Its lead investigational compound, blarcamesine (ANAVEX®2-73), is an orally available sigma-1 receptor (S1R) agonist being evaluated for its potential to treat a range of neurological conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Director's Dealing 2025 | 2025-08-22 | English | |
| FORM 10-Q | 2025-08-12 | English | |
| FORM 8-K | 2025-07-26 | English | |
| FORM 424B5 | 2025-07-25 | English | |
| Regulatory Filings 2025 | 2025-07-24 | English | |
| Regulatory Filings 2025 | 2025-07-21 | English |
Browse filings by year
22 years- 2026 8 filings
- 2025 33 filings
- 2024 28 filings
- 2023 22 filings
- 2022 25 filings
- 2021 37 filings
- 2020 26 filings
- 2019 25 filings
- 2018 24 filings
- 2017 44 filings
- 2016 34 filings
- 2015 39 filings
- 2014 27 filings
- 2013 20 filings
- 2012 13 filings
- 2011 36 filings
- 2010 34 filings
- 2009 19 filings
- 2008 20 filings
- 2007 26 filings
- 2006 19 filings
- 2005 18 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 11802207 | Director's Dealing 2025 | 2025-08-22 | English | ||
| 11802206 | FORM 10-Q | 2025-08-12 | English | ||
| 11802209 | FORM 8-K | 2025-07-26 | English | ||
| 11802210 | FORM 424B5 | 2025-07-25 | English | ||
| 11802211 | Regulatory Filings 2025 | 2025-07-24 | English | ||
| 11802212 | Regulatory Filings 2025 | 2025-07-21 | English | ||
| 11802213 | Regulatory Filings 2025 | 2025-07-21 | English | ||
| 11802214 | FORM S-3 | 2025-07-14 | English | ||
| 11802215 | FORM 8-K | 2025-07-03 | English | ||
| 11802218 | FORM 8-K | 2025-06-13 | English | ||
| 11802219 | Director's Dealing 2025 | 2025-06-09 | English | ||
| 11802228 | FORM 10-Q | 2025-05-13 | English | ||
| 11802229 | Director's Dealing 2025 | 2025-05-01 | English | ||
| 11802230 | Director's Dealing 2025 | 2025-05-01 | English | ||
| 11802233 | ARS | 2025-04-25 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
ANAVEX LIFE SCIENCES CORP. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32464/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32464 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32464 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32464 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32464}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ANAVEX LIFE SCIENCES CORP. (id: 32464)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.